Drug delivery companies develop technologies, formulations and platforms that control how, where and when therapeutic agents are released in the body. The field focuses on improving treatment efficacy, reducing side effects and helping medicines reach their intended targets safely and efficiently.
This category includes companies working on:
Browse 119 UK drug delivery companies below.
Non-viral intracellular delivery platform based on biomolecular condensates
PartitionBio is a biotechnology company developing a non-viral intracellular delivery platform based on liquid-liquid phase separation and biomolecular condensates. Its lead product, BubbleFect, is a room-temperature-stable, non-lipid reagent designed for bench-top use without specialist equipment or cold-chain…
Surface acoustic wave nebuliser platform for inhaled drug delivery
Nebu~Flow is a UK medical technology company developing next-generation nebuliser devices using patented surface acoustic wave technology to aerosolise drugs into precisely controlled droplet sizes for deep lung deposition. The platform is designed to enable inhalation delivery of biologics, RNA-based formulations,…
One-step encapsulation drug delivery platform for advanced therapeutics
PNAS Therapeutics is a UK-based drug delivery company developing a one-step encapsulation platform designed to simplify complex pharmaceutical manufacturing processes. The platform enhances local delivery through improved bioavailability and targeting, is compatible with multiple active pharmaceutical ingredients, and…
Preventing cancer therapy side effects with topical medicines
VasoDynamics is a clinical-stage pharmaceutical development company focused on preventing the debilitating side effects of cancer therapy. The company develops topical formulations targeting radiation-induced oral mucositis, dermatitis, and chemotherapy-induced hair loss, using vasoconstrictor and radioprotective…
Investigational oral ketamine formulations for treatment-resistant depression
Neurocentrx Pharma is a clinical-stage biopharmaceutical company developing oral ketamine formulations for treatment-resistant mood disorders. Its NRCx-201 programme includes immediate-release and abuse-deterrent capsules intended for clinically supervised treatment and potentially supported home care. Following…
Oral and injectable peptide therapies for obesity and cardiometabolic disease
Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders. Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology…
Curative genetic medicines for peripheral nerve diseases
CureAge Therapeutics develops genetic medicines for peripheral nerve disorders, initially targeting neurofibromatosis type 1 (NF1). Its investigational platform uses locally delivered lipid nanoparticles to carry genetic material into Schwann cells, aiming to restore NF1 gene function and address surrounding tumour…
Thermostable vaccine formulations delivered through microneedle patches
Microneedle Solutions is a biotechnology company developing vaccine-containing microneedle patches for self-administration. Its platform combines a patented needle-array manufacturing process with vaccine-loaded matrices intended to protect biological payloads and enable delivery through the skin. The company has…
Pharmaceutical formulation development and clinical manufacturing services
SGS Quay Pharma is a contract development and manufacturing organisation providing formulation development, analytical services, and clinical trial manufacturing for pharmaceutical and biotechnology companies. The company specialises in dosage form design for APIs with challenging solubility and bioavailability…
Pharmaceutical development, clinical pharmacology and GMP manufacturing
Seda Pharmaceutical Development Services is a provider of integrated pharmaceutical development, clinical pharmacology and GMP manufacturing services to the pharma and biotech sectors. The company supports clients from early-stage drug development through clinical trials to regulatory approval, with particular…
Specialist CRO for inhaled and nasal drug product development
Nanopharm is a contract research organisation specialising in the development of orally inhaled and nasal drug products, providing formulation development, materials characterisation, analytical testing, and in vitro and in silico modelling services to pharmaceutical and biotechnology clients. The company supports…
Engineered immune cells as living delivery vehicles for genetic medicines
Dart Biosciences is a biotechnology company developing a platform that uses engineered immune cells as living delivery vehicles for genetic medicines. By leveraging immune cells' natural ability to localise to disease-relevant tissues, the platform aims to achieve more spatially precise genetic payload transfer with…
Xeno nucleic acid binders for targeted drug delivery
Xterna is a biotechnology company developing cell-specific molecular binders composed of xeno nucleic acids (XNAs), chemically modified nucleic acids distinct from naturally occurring DNA and RNA. XNA-based binders are engineered to target cell types that evade conventional antibody-based approaches, enabling drug…
Engineered cell-derived vesicles for targeted RNA and drug delivery
AAB Therapeutics develops programmable nanovesicles from engineered human cell membranes for targeted intracellular drug delivery. The vesicles are designed to carry RNA, small molecules or biologics, using surface targeting molecules and fusogenic proteins to release their cargo into cells. The preclinical company…
Plant protein materials replacing plastics and microplastics
Xampla is a Cambridge-based materials innovation company developing plant protein-based alternatives to single-use plastics and synthetic microplastics. Its range of products includes biodegradable coatings, soluble films, edible films, and microcapsules derived from sustainable vegetable proteins such as pea,…
Micellar oral cannabidiol formulation for psychiatric drug development
NWPharmaTech is a clinical-stage biotechnology company developing investigational oral cannabidiol formulations for psychiatric disorders. Its NWPT-SM32300 programme uses a high-loading micellar softgel intended to deliver consistent oral doses. The company reports completion of a Phase 1 pharmacokinetic and…
Contract research using in vitro models of the human gut
Aelius Biotech is a contract research organisation using laboratory models of the human digestive tract to study drugs, nutritional products and functional foods. Its animal-free systems help customers explore how formulations behave during digestion and provide evidence for product development. The company works with…
Microgravity-based CDMO platform for crystallisation of biologic drugs
BioOrbit is a biotech developing a proprietary hardware platform for the crystallisation of protein-based biologic drugs in low Earth orbit. The company exploits the absence of gravity-driven convection in microgravity to produce larger, more uniform protein crystals than ground-based methods allow, enabling…
Viral vector platform for solid tumour immunotherapy
Akamis Bio is a clinical-stage oncology company developing oncolytic adenoviral therapeutics for solid tumours. Its platform delivers immunotherapeutic payloads directly to tumour sites following intravenous dosing, enabling tumour-localised expression of proteins including CD40 agonist antibodies and cytokines. Lead…
Lyophilisation equipment, CDMO services, and freeze-drying expertise
Biopharma Group is a contract development and manufacturing organisation and capital equipment supplier specialising in lyophilisation and liquid formulation technologies. The company serves pharmaceutical, biotechnology, and diagnostics clients across two divisions: an equipment sales and technical service division…